Načítá se...
Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis
Glioblastoma (GBM) is a highly lethal malignant brain tumor that expresses proangiogenic factors, including vascular endothelial growth factor (VEGF). Bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA), a monoclonal antibody against VEGF, is routinely used in the U.S. to treat GBM pati...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AlphaMed Press
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3228073/ https://ncbi.nlm.nih.gov/pubmed/21948651 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0047 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|